BioNTech
NEWS
As the FDA prepares to discuss booster shots for Moderna and J&J vaccines, a new study came out suggesting that mixing and matching vaccines works well and is safe.
Teamed up with pharma giant GlaxoSmithKline, CureVac is now focusing on a more promising target – second-generation mRNA vaccines.
Although there are many effective and safe COVID-19 vaccines around the world, the preferred vaccine is the Pfizer-BioNTech vaccine. For that and more stories, read on.
As US vaccination rates have been hovering in the 50% of the population range for two months, President Biden hit the old dusty trail to push his vaccine mandate even more.
Here’s a look at mRNA vaccines and their effectiveness and more COVID-19 news.
Moderna seeks to invalidate two patents of Arbutus Biopharma Corp. The company hopes to appeal a preemptive challenge to the patents upheld by the U.S. Patent Trial and Appeals Board.
There is — still — plenty of news about COVID-19 and new drugs, therapies and FDA applications. Here’s a look.
Johnson & Johnson is expected to ask the U.S. Food and Drug Administration to authorize a booster for its one-shot COVID-19 vaccine this week.
First COVID-19, now cancer. BioNTech made history when its COVID-19 mRNA vaccine with partner Pfizer became the first ever approved.
JOBS
IN THE PRESS